Brigatinib (formerly AP26113; AP-26113; ALK-IN-1; trade name: Alunbrig) is an orally bioavailable, FDA-approved and selective ALK (anaplastic lymphoma kinase) inhibitor with potential antineoplastic activity.

TAE684 (also called NVP-TAE684; TAE-684) is a novel, highly potent and selective small-molecule inhibitor of the ALK (anaplastic lymphoma kinase) tyrosine kinase with potential anticancer activity.

Ceritinib diHCl (LDK-378; LDK378; Zykadia; Spexib), the dihydrochloride salt of ceritinib, is an ALK (anaplastic lymphoma kinase positive) inhibitor approved in 2014 for the treatment of non-small cell lung cancer (NSCLC).

Loratinib (formerly also known as Lorlatinib, PF-06463922; trade name: Lorbrena) is a potent, orally bioavailable, brain-penetrant, ATP-competitive, and dual ALK/ROS1 inhibitor with potential antitumor activity.

Alectinib (formerly AF802, CH5424802, RO5424802; trade name Alecensa) is a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor with potential antitumor activity.

MS4078 is a potent PROTAC degrader of anaplastic lymphoma kinase (ALK) with a Kd of 19 nM for binding affinity to ALK.

ALK inhibitor 2 is a novel, potent and selective inhibitor for the ALK kinase (anaplastic lymphoma kinase).

ZX-29 is a novel and potent ALK inhibitor.

ASP3026 (ASP-3026; ASP 3026) is an orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) with potential antineoplastic activity.

Ensartinib (formerly known as X-396) is a novel, highly potent, selective, and orally available small molecule inhibitor of ALK (anaplastic lymphoma kinase) with an IC50 less than 4 nM in Ambit assays.